Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy [clinicaltrials:NCT00017719]

Bio2RDF identifier

NCT00017719

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00017719

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00017719

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

The best anti-HIV treat ...... ransmission during pregnancy.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Combination Treatment With and ...... HIV Infection During Pregnancy

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery) [clinicaltrials_resource:1a50306d29856a3f70b342f8dd9d5581]

Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery) [clinicaltrials_resource:2f19efd9eaafc5d6c9a1e1366eb0dfea]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery) [clinicaltrials_resource:16172e5452dac6c171b9e936a40c9eef]

Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery) [clinicaltrials_resource:17011e1ba726fe9e6edf425a9f94c4e3]

Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery) [clinicaltrials_resource:211d967c5260c16aa8910adfbaf915d4]

Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery) [clinicaltrials_resource:35836adae0eafcb930390eca7b7e964f]

Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery) [clinicaltrials_resource:4bd350e075e879b3e3d46b9602958cb3]

Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery) [clinicaltrials_resource:5200b593c4f937d64cb4a37dd00eeef4]

Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery) [clinicaltrials_resource:6a56d9151c3cddfedf20992eed09024c]

Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery) [clinicaltrials_resource:a7f8787f248abf7756b65ddc142cbc5e]

Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery) [clinicaltrials_resource:b4f0bad13ce413f23545bc3c6a5eb399]

Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery) [clinicaltrials_resource:e2b8fb017bab3592c217ece176f9ed82]

collaborator [clinicaltrials_vocabulary:collaborator]

National Institute of Allergy and Infectious Diseases (NIAID) [clinicaltrials_resource:d9a74aeb9c0d0448f38e08189395de72]

completion date [clinicaltrials_vocabulary:completion-date]

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

The optimal treatment s ...... the postpartum period.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00017719 [clinicaltrials_resource:15c60d49a560e6ac8bd7e72167c377f2]

enrollment [clinicaltrials_vocabulary:enrollment]

440

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2001-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

intervention [clinicaltrials_vocabulary:intervention]

Lamivudine/Zidovudine [clinicaltrials_resource:5331ba3b284a6d38b8b919e9fd6578e3]

Lamivudine [clinicaltrials_resource:84bc89e9bcc3d7649690e2405b015ae0]

Zidovudine [clinicaltrials_resource:8f742995bc0545df41d3f8e8ed83e9b0]

Nevirapine [clinicaltrials_resource:efec8a49f3bae1c2b49921e7cede0b61]

Nelfinavir mesylate [clinicaltrials_resource:f5fe97a67bf5bd48312831ea81e08ccd]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Nelfinavir [clinicaltrials_resource:1465f6bcc84621c4157f80921afa4762]

Lamivudine, zidovudine drug combination [clinicaltrials_resource:3319b7ff39d601e15700e255d11669d0]

Zidovudine [clinicaltrials_resource:346d493fac3d7cb8c59c22783c490a8e]

Lamivudine [clinicaltrials_resource:5ed6d943113301b6ad74e2aa6171512a]

HIV Protease Inhibitors [clinicaltrials_resource:87f32e2e91d9dd343a85cd9e8fe09ea0]

Reverse Transcriptase Inhibitors [clinicaltrials_resource:9e1536af6b9d95e1c13f94cef30497a0]

Protease Inhibitors [clinicaltrials_resource:bd458628804b4d5762575e9ef3be9215]

keyword [clinicaltrials_vocabulary:keyword]

Anti-HIV Agents

http://www.w3.org/2001/XMLSchema#string

Combivir

http://www.w3.org/2001/XMLSchema#string

HIV Protease Inhibitors

http://www.w3.org/2001/XMLSchema#string

Pregnancy Complications, Infectious

http://www.w3.org/2001/XMLSchema#string

Reverse Transcriptase Inhibitors

http://www.w3.org/2001/XMLSchema#string

Treatment Naive

http://www.w3.org/2001/XMLSchema#string

Viral Load

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2013-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

National Institute of Allergy and Infectious Diseases (NIAID) [clinicaltrials_resource:d9a74aeb9c0d0448f38e08189395de72]

link [clinicaltrials_vocabulary:link]

Click here for more information about lamivudine [clinicaltrials_resource:1828ad7a9c74adc7f6680dba1eba4583]

Haga clic aquí para ver información sobre este ensayo clínico en español. [clinicaltrials_resource:57213e660bf6056cc04646fb86b54641]

Click here for more information about HIV and pregnancy [clinicaltrials_resource:6deff299f7211ec6e0278af897ab67b0]

Click here for more information about nevirapine [clinicaltrials_resource:7817a00bc155a693fa997e48bb3dcfbc]

Click here for more information on medication safety during pregnancy [clinicaltrials_resource:9f99f3f3627b0206071a26820b820646]

Click here for more information about zidovudine [clinicaltrials_resource:bbd0409212310adc20b4a71fef56f286]

Click here for more information about medication for HIV positive pregnant women [clinicaltrials_resource:d2e561af0bae6e7989f50b4e554f85e2]

Click here for more information about nelfinavir [clinicaltrials_resource:d828acd4d32a6ac1c2943c4e65040211]

Click here for more information about lamivudine/zidovudine [clinicaltrials_resource:f8674dbc65d4191c4e5196cf7f6ec7da]

location [clinicaltrials_vocabulary:location]

Usc La Nichd Crs [clinicaltrials_resource:23bd4bbb387c93b59762f36e53c95b08]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00017719

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

Randomized Trial of Protease I ...... HIV Infection During Pregnancy

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

P1022

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Jane Hitti, MD, MPH [clinicaltrials_resource:ab93e7d0ec4c64a49ff6b7770d250a69]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:77fa11db9aea1d8cd0ff35db5bc538f2]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

reference [clinicaltrials_vocabulary:reference]

14977385 [pubmed:14977385]

15778108 [pubmed:15778108]

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

10,192

http://www.w3.org/2001/XMLSchema#integer

source [clinicaltrials_vocabulary:source]

National Institute of Allergy and Infectious Diseases (NIAID) [clinicaltrials_resource:d9a74aeb9c0d0448f38e08189395de72]

start date [clinicaltrials_vocabulary:start-date]

2002-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00017719 study design [clinicaltrials_resource:bbdc1f73a7b894bfe4c347c36a342dd0]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00017719

verification date [clinicaltrials_vocabulary:verification-date]

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00017719

http://www.w3.org/2001/XMLSchema#string

title

Combination Treatment With and ...... HIV Infection During Pregnancy

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Combination Treatment With and ...... y [clinicaltrials:NCT00017719]

@en